Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10390219 | 0.77 | HTR1A (0.37) | HTR1A | |
| SCHEMBL9067653 | 0.77 | HTR1A (0.37) | HTR1A | |
| SCHEMBL7977539 | 0.75 | GRIN2B (0.43) | HTR1ASIGMAR1 | |
| SCHEMBL10390238 | 0.75 | HTR1A (0.38) | HTR1A | |
| SCHEMBL3433317 | 0.71 | DRD2 (0.36) | HTR1ASIGMAR1 | |
| SCHEMBL2183528 | 0.67 | PDPK1 (0.37) | — | |
| SCHEMBL3653495 | 0.67 | PLAU (0.41) | — | |
| SCHEMBL1383876 | 0.67 | ANPEP (0.39) | — | |
| SCHEMBL6429735 | 0.67 | CYP19A1 (0.50) | HTR1ASIGMAR1 | |
| SCHEMBL3100368 | 0.67 | HTR1A (0.55) | HTR1ASIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050154216-A1 | Novel enantiomeric compounds for treatment of cardiac arrhythmias and methods of use | ARYX THERAPEUTICS | 2005-07-14 | — | — | US | claimed |
| US-9840464-B2 | IAP binding compounds | TetraLogic Birinapant UK Ltd. (GB) | 2017-12-12 | — | — | US | disclosed |
| US-20160289183-A1 | IAP Binding Compounds | TETRALOGIC PHARMACEUTICALS CORPORATION | 2016-10-06 | — | — | US | disclosed |
| US-9394249-B2 | IAP binding compounds | TetraLogic Birinapant UK Ltd. (GB) | 2016-07-19 | — | — | US | disclosed |
| US-20150307448-A1 | IAP Binding Compounds | TETRALOGIC PHARMACEUTICALS CORPORATION (US) | 2015-10-29 | — | — | US | disclosed |
| US-8802716-B2 | IAP binding compounds | TETRALOGIC PHARMACEUTICALS CORPORATION (US) | 2014-08-12 | — | — | US | disclosed |
| US-20130289075-A1 | IAP BINDING COMPOUNDS | TETRALOGIC PHARMACEUTICALS CORPORATION | 2013-10-31 | — | — | US | disclosed |
| US-20110294827-A1 | IAP BINDING COMPOUNDS | TETRALOGIC PHARMACEUTICALS CORPORATION (US) | 2011-12-01 | — | — | US | disclosed |
| US-7968590-B2 | IAP binding compounds | TETRALOGIC PHARMACEUTICALS CORPORATION (US) | 2011-06-28 | — | — | US | disclosed |
| US-20090048183-A1 | IAP BINDING COMPOUNDS | TETRALOGIC PHARMACEUTICALS CORPORATION (US) | 2009-02-19 | — | — | US | disclosed |
| US-7456209-B2 | IAP binding compounds | TETRALOGIC PHARMACEUTICALS CORPORATION (US) | 2008-11-25 | — | — | US | disclosed |
| US-20080280834-A1 | Compounds and methods for inhibiting apoptosis | UNIVERSITY OF PITTSBURGH OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2008-11-13 | — | — | US | disclosed |
| EP-1963364-A2 | COMPOUNDS AND METHODS FOR INHIBITING APOPTOSIS | University of Pittsburgh - Of the Commonwealth System of Higher Education (US) | 2008-09-03 | — | — | EP | disclosed |
| WO-2007064997-A2 | COMPOUNDS AND METHODS FOR INHIBITING APOPTOSIS | UNIVERSITY OF PITTSBURGH OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2007-06-07 | — | — | WO | disclosed |
| EP-1773766-A2 | IAP BINDING COMPOUNDS | TETRALOGIC PHARMACEUTICALS CORPORATION (US) | 2007-04-18 | — | — | EP | disclosed |
| WO-2006020060-A2 | IAP BINDING COMPOUNDS | TETRALOGIC PHARMACEUTICALS CORPORATION (US) | 2006-02-23 | — | — | WO | disclosed |
| US-20060025347-A1 | IAP binding compounds | MEDIVIR AB (SE) | 2006-02-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160289183-A1 | IAP Binding Compounds | BIRC5, API5, BIRC2 | HTR1A 4465/4885SIGMAR1 4356/4885 |
| US-20130289075-A1 | IAP BINDING COMPOUNDS | API5, BIRC5, BIRC2 | HTR1A 4474/4885SIGMAR1 4376/4885 |
| US-20080280834-A1 | Compounds and methods for inhibiting apoptosis | BAX, CASP3, BCL2 | HTR1A 2622/4885SIGMAR1 4655/4885 |
| US-20150307448-A1 | IAP Binding Compounds | BIRC5, API5, BIRC2 | HTR1A 4465/4885SIGMAR1 4356/4885 |
| US-20110294827-A1 | IAP BINDING COMPOUNDS | BIRC5, BIRC2, API5 | HTR1A 4419/4885SIGMAR1 4357/4885 |
| US-20060025347-A1 | IAP binding compounds | BIRC5, BIRC2, API5 | HTR1A 4419/4885SIGMAR1 4357/4885 |
| US-20090048183-A1 | IAP BINDING COMPOUNDS | BIRC5, BIRC2, API5 | HTR1A 4419/4885SIGMAR1 4357/4885 |
| US-20050154216-A1 | Novel enantiomeric compounds for treatment of cardiac arrhythmias and methods of use | RYR2, KCNN2, KCNH2 | HTR1A 2535/4885SIGMAR1 2651/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.